In 2012/13, blood glucose test strips (BGTS) were the second most expensive product reimbursed through the Ontario Public Drug Program costing the province $139 million that year.
In 2013, Ontario was one of the first payers to introduce a policy limiting reimbursements for BGTS aligned with recommendations from the Canadian Diabetes Association. This study investigates the impact of this policy on patient outcomes among adults with diabetes in Ontario.
Access the full article and associated resources: